Shandong Kaisheng New Materials (301069)2025-04-18 08:40Financial Performance - The company's revenue for Q1 2025 was CNY 269,395,580.18, representing a 12.28% increase compared to CNY 239,937,179.44 in the same period last year[5]. - Net profit attributable to shareholders was CNY 30,670,161.17, up 19.35% from CNY 25,698,384.59 year-on-year[5]. - The net profit after deducting non-recurring gains and losses increased by 27.72%, reaching CNY 27,689,248.68 compared to CNY 21,679,169.31 in the previous year[5]. - Total operating revenue for the current period reached ¥269,395,580.18, an increase of 12.4% compared to ¥239,937,179.44 in the previous period[19]. - Operating profit for the current period was ¥37,670,368.76, up from ¥31,233,126.62, reflecting a growth of 20.8%[20]. - Net profit attributable to the parent company was ¥30,670,161.17, compared to ¥25,698,384.59 in the previous period, marking an increase of 19.3%[20]. - The company reported a basic and diluted earnings per share of ¥0.0729, compared to ¥0.0611 in the previous period, an increase of 19.7%[20]. Cash Flow and Investments - The company's cash flow from operating activities decreased significantly by 79.18%, amounting to CNY 2,858,216.65, down from CNY 13,726,887.23 in Q1 2024[5]. - Cash flow from operating activities was ¥131,558,597.52, down from ¥181,110,877.58, indicating a decrease of 27.4%[22]. - The net increase in cash and cash equivalents was 404,841,682.46 last year[24]. - The ending balance of cash and cash equivalents stood at 415,726,948.25 in the previous period[24]. - The company received 800,684,537.59[23]. - Cash received from investment income was 1,887,467.14 in the previous year[23]. - Cash paid for the purchase of fixed assets and intangible assets was 2,558,233.48[23]. Assets and Liabilities - Total assets at the end of Q1 2025 were CNY 2,410,569,005.89, a 0.91% increase from CNY 2,388,723,256.19 at the end of the previous year[5]. - Total current assets amounted to ¥1,407,470,348.44, up from ¥1,348,622,039.44, representing a growth of approximately 4.3%[16]. - The company's fixed assets decreased to ¥660,189,685.87 from ¥682,377,368.42, a decline of about 3.2%[16]. - Total liabilities decreased to ¥743,702,051.64 from ¥752,641,539.99, indicating a reduction of 1.8%[18]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 22,203[11]. - The largest shareholder, Huabang Life Health, holds 44.51% of shares, totaling 187,216,000 shares[11]. - The number of shares held by the top ten unrestricted shareholders includes 187,216,000 shares from Huabang Life Health[11]. - Wang Jiarong and Wang Yong, both significant shareholders, have locked shares totaling 12,000,000 and 11,760,000 respectively[14]. - The company has not reported any changes in the participation of major shareholders in margin trading[12]. Research and Development - Research and development expenses surged by 86.34% to CNY 19,541,083.56, reflecting increased investment in R&D[9]. - Research and development expenses increased significantly to ¥19,541,083.56, up from ¥10,486,648.77, representing an increase of 86.7%[19]. Equity and Returns - The weighted average return on equity improved to 1.86%, up from 1.53% in the same period last year[5]. - The total equity attributable to shareholders increased by 1.88% to CNY 1,666,866,954.25 compared to CNY 1,636,081,716.20 at the end of the previous year[5]. - The total equity attributable to shareholders increased to ¥1,666,866,954.25 from ¥1,636,081,716.20, reflecting a growth of 1.9%[18]. Other Information - There are no new strategies or significant developments reported in the current quarter[15]. - The company did not conduct an audit for the first quarter report[25].